Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
ALT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.90 - $11.16
Previous CloseN/A
Volume1.55M
Average Volume (3M)2.86M
Market Cap
$333.61M
Enterprise Value$148.02M
Total Cash (Recent Filing)$183.10M
Total Debt (Recent Filing)$15.85M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 11, 2025EPS Estimate
-0.27Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding88,257,256
10 Day Avg. Volume2,549,798
30 Day Avg. Volume2,861,116
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue7.40K
Enterprise Value/Gross Profit-14.80K
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$20.63Price Target Upside420.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPemvidutide’s dual GLP-1/glucagon mechanism positions it for differentiation and future combination optionality as the field trends toward pairing incretins with fibroblast growth factor 21 (FGF21) approaches.
Financial PerformancePemvidutide may generate peak annual revenues of over $1B in MASH if approved.
Strategic AcquisitionsRoche’s agreement to acquire 89bio for up to ~$3.5B underscores intensifying large-cap conviction in Metabolic Dysfunction-Associated Steatohepatitis (MASH) and combination strategies—providing a positive read-through to pemvidutide ahead of two catalysts.
Bears Say
Market CompetitionPemvidutide lacks clear differentiation in the increasingly competitive MASH market.
Regulatory ChallengesNon-invasive tests cannot form the basis of regulatory approval at this time.
Stock PerformancePemvidutide missed on 1-point improvement in fibrosis, causing the stock to trade down ~50%, as investors were expecting significant results on both co-primary endpoints.
Altimmune News
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.90 and its highest was $11.16 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $333.61M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 11, 2025 which is in 49 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 12, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.336 by $0.066.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.27.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 88,257,256 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.336. Following the earnings report the stock price went up 7.101%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in ALT
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.63 (420.96% Upside)
$20.63 (420.96% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 142.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.06%
12-Months-Change
Fundamentals
Return on Equity
-55.91%
Trailing 12-Months
Asset Growth
9.81%
Trailing 12-Months
Company Description
Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a largely positive outlook for Altimmune, emphasizing significant advances in clinical trials, particularly for NASH, and a strong financial position. However, challenges remain in achieving statistical significance for fibrosis improvement and navigating regulatory pathways for noninvasive testing.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$20.63
▲(420.96% Upside)
Technical Analysis
Autolus Therapeutics
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Inventiva
―
Sana Biotechnology
―
Ownership Overview
0.72% Insiders
10.56% Mutual Funds
14.20% Other Institutional Investors
63.15% Public Companies and Individual Investors